TLR-4 expression and decrease in chronic inflammation: Indicators of aggressive follicular thyroid carcinoma

Journal of Clinical Pathology

Volumn 65, Issue 4, 2012, Pages 333-338

  Hagström, Jaana ^a,b   Heikkilä, Annukka ^a   Siironen, Päivi ^c   Louhimo, Johanna ^c   Heiskanen, Ilkka ^c   Mäenpää, Hanna ^c   Arola, Johanna ^a   Haglund, Caj ^a,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ADENOMA; AGGRESSIVE FOLLICULAR THYROID CARCINOMA; ARTICLE; CARCINOMA; CHRONIC INFLAMMATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; METASTASIS; OXYPHILIC TUMOUR; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CARCINOMA;

ANTIGENS, CD45; CELL TRANSFORMATION, NEOPLASTIC; CHRONIC DISEASE; HASHIMOTO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; THYROID NEOPLASMS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TUMOR MARKERS, BIOLOGICAL;

EID: 84858702848     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200402     Document Type: Article

References (39)

1. Ghossein R. Encapsulated malignant follicular cell-derived thyroid tumors. Endocr Pathol 2010;21:212-18.
2. Sobrinho-Simoes M, Asa SL, Kroll TG, et al. Follicular carcinoma. In: DeLellis RA, Lloyd RV, Heitz PU, et al, eds. Pathology and Genetics Tumours of Endocrine Organs. 10 World Health Organization Classification of Tumours. Lyon: IARC Press, 2004:67-72.
3. Heikkila A, Siironen P, Hagstrom J, et al. Follicular thyroid neoplasm: clinicopathologic features suggesting malignancy. APMIS 2010;118:846-54.
4. Chen K, Huang J, Gong W, et al. Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol 2007;7:1271-85. (Pubitemid 47126372)
5. Kluwe J, Mencin A, Schwabe RF. Toll-like receptors, wound healing, and carcinogenesis. J Mol Med 2009;87:125-38.
6. Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009;9:57-63.
7. Killeen SD, Wang JH, Andrews EJ, et al. Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword? Br J Cancer 2006;95:247-52. (Pubitemid 44187583)
8. Mkaddem SB, Bens M, Vandewalle A. Differential activation of Toll-like receptor-mediated apoptosis induced by hypoxia. Oncotarget 2010;1:741-50.
9. Wolska A, Lech-Maranda E, Robak T. Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett 2009;14:248-72.
10. Grote K, Schuett H, Salguero G, et al. Toll-like receptor 2/6 stimulation promotes angiogenesis via GM-CSF as a potential strategy for immune defense and tissue regeneration. Blood 2010;115:2543-52.
11. Simiantonaki N, Kurzik-Dumke U, Karyofylli G, et al. Reduced expression of TLR4 is associated with the metastatic status of human colorectal cancer. Int J Mol Med 2007;20:21-9.
12. Szczepanski M, Stelmachowska M, Stryczynski L, et al. Assessment of expression of toll-like receptors 2, 3 and 4 in laryngeal carcinoma. Eur Arch Otorhinolaryngol 2007;264:525-30. (Pubitemid 46569951)
13. Zhang YB, He FL, Fang M, et al. Increased expression of Toll-like receptors 4 and 9 in human lung cancer. Mol Biol Rep 2009;36:1475-81.
14. Hatakeyama M, Higashi H. Helicobacter pylori CagA: a new paradigm for bacterial carcinogenesis. Cancer Sci 2005;96:835-43. (Pubitemid 43056121)
15. Imai T, Hasumura M, Onose J, et al. Development of invasive follicular cell carcinomas in a rat thyroid carcinogenesis model: biological impact of capsular inflammation and reduced cyclooxygenase-2 expression. Cancer Sci 2005;96:31-7. (Pubitemid 40310022)
16. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008;454:436-44.
17. Muzza M, Degl'Innocenti D, Colombo C, et al. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clin Endocrinol (Oxf) 2010;72:702-8.
18. Kim S, Karin M. Role of TLR2-dependent inflammation in metastatic progression. Ann N Y Acad Sci 2011;1217:191-206.
19. Guarino V, Castellone MD, Avilla E, et al. Thyroid cancer and inflammation. Mol Cell Endocrinol 2010;321:94-102.
20. Chan J, Hirokawa M, Evans H, et al. Follicular adenoma. In: DeLellis RA, Lloyd RV, Heitz PU, et al, eds. Pathology and Genetics Tumours of Endocrine Organs. World Health Organization Classification of Tumours. Lyon: IARC Press, 2004:98-103.
21. Sobrinho-Simoes M, Albores-Saveedra J, Tallini G, et al. Poorly differentiated carcinoma. In: DeLellis RA, Lloyd RV, Heitz PU, et al, eds. Pathology and Genetics Tumours of Endocrine Organs. World Health Organization Classification of Tumours. Lyon: IARC Press, 2004:73-6.
22. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol Pharm Bull 2005;28:886-92. (Pubitemid 40740661)
23. Nicola JP, Velez ML, Lucero AM, et al. Functional toll-like receptor 4 conferring lipopolysaccharide responsiveness is expressed in thyroid cells. Endocrinology 2009;150:500-8.
24. Ioannou S, Voulgarelis M. Toll-like receptors, tissue injury, and tumourigenesis. Mediators Inflamm 2010;2010:581837.
25. Andreani V, Gatti G, Simonella L, et al. Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. Cancer Res 2007;67:10519-27. (Pubitemid 350070828)
26. He W, Liu Q, Wang L, et al. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 2007;44:2850-9. (Pubitemid 46412506)
27. Lee CH, Wu CL, Shiau AL. Toll-like receptor 4 signaling promotes tumor growth. J Immunother 2010;33:73-82.
28. Wang EL, Qian ZR, Nakasono M, et al. High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer 2010;102:908-15.
29. Gonzalez-Reyes S, Marin L, Gonzalez L, et al. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer 2010;10:665.
30. Gatti G, Quintar AA, Andreani V, et al. Expression of Toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer. Prostate 2009;69:1387-97.
31. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
32. Solinas G, Marchesi F, Garlanda C, et al. Inflammation-mediated promotion of invasion and metastasis. Cancer Metastasis Rev 2010;29:243-8.
33. Shaha AR. Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer. Laryngoscope 2004;114:393-402. (Pubitemid 38391898)
34. Jukkola A, Bloigu R, Ebeling T, et al. Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. Endocr Relat Cancer 2004;11:571-9. (Pubitemid 39331285)
35. Lang W, Choritz H, Hundeshagen H. Risk factors in follicular thyroid carcinomas. A retrospective follow-up study covering a 14-year period with emphasis on morphological findings. Am J Surg Pathol 1986;10:246-55. (Pubitemid 16069390)
36. Maximo V, Sobrinho-Simoes M. Hurthle cell tumours of the thyroid. A review with emphasis on mitochondrial abnormalities with clinical relevance. Virchows Arch 2000;437:107-15. (Pubitemid 30623568)
37. Wada N, Duh QY, Miura D, et al. Chromosomal aberrations by comparative genomic hybridization in hurthle cell thyroid carcinomas are associated with tumor recurrence. J Clin Endocrinol Metab 2002;87:4595-601. (Pubitemid 35247046)
38. Finley DJ, Zhu B, Fahey TJ. Molecular analysis of Hurthle cell neoplasms by gene profiling. Surgery 2004;136:1160-8. (Pubitemid 39647529)
39. Pu RT, Yang J, Wasserman PG, et al. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration? Diagn Cytopathol 2006;34:330-4.